Article thumbnail

Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Triggers, Causes, and Outcome (SECRETO): Rationale and design

By Jukka Putaala, Nicolas Martinez-Majander, Sahrai Saeed, Nilufer Yesilot, Pekka Jäkälä, Ossi Nerg, Georgios Tsivgoulis, Heikki Numminen, Daniel Gordin, Bettina von Sarnowski, Ulrike Waje-Andreassen, Pauli Ylikotila, Risto O Roine, Marialuisa Zedde, Juha Huhtakangas, Catarina Fonseca, Petra Redfors, Frank-Erik de Leeuw, Alessandro Pezzini, Janika Kõrv, Siim Schneider, Christian Tanislav, Christian Enzinger, Dalius Jatuzis, Bob Siegerink, Patricia Martínez-Sánchez, Armin J Grau, Frederick Palm, Per-Henrik Groop, Sylvain Lanthier, Hugo Ten Cate, Pirkko Pussinen, Susanna Paju, Juha Sinisalo, Mika Lehto, Arne Lindgren, José Ferro, Steven Kittner, Franz Fazekas, Eva Gerdts and Turgut Tatlisumak


Background: Worldwide, about 1.3 million annual ischaemic strokes (IS) occur in adults aged <50 years. Of these early-onset strokes, up to 50% can be regarded as cryptogenic or associated with conditions with poorly documented causality like patent foramen ovale and coagulopathies. Key hypotheses/aims: (1) Investigate transient triggers and clinical/sub-clinical chronic risk factors associated with cryptogenic IS in the young; (2) use cardiac imaging methods exceeding state-of-the-art to reveal novel sources for embolism; (3) search for covert thrombosis and haemostasis abnormalities; (4) discover new disease pathways using next-generation sequencing and RNA gene expression studies; (5) determine patient prognosis by use of phenotypic and genetic data; and (6) adapt systems medicine approach to investigate complex risk-factor interactions. Design: Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO; NCT01934725) is a prospective multi-centre case–control study enrolling patients aged 18–49 years hospitalised due to first-ever imaging-proven IS of undetermined etiology. Patients are examined according to a standardised protocol and followed up for 10 years. Patients are 1:1 age- and sex-matched to stroke-free controls. Key study elements include centralised reading of echocardiography, electrocardiography, and neurovascular imaging, as well as blood samples for genetic, gene-expression, thrombosis and haemostasis and biomarker analysis. We aim to have 600 patient– control pairs enrolled by the end of 2018. Summary: SECRETO is aiming to establish novel mechanisms and prognosis of cryptogenic IS in the young and will provide new directions for therapy development for these patients. First results are anticipated in 2019

Publisher: 'SAGE Publications'
Year: 2017
DOI identifier: 10.1177/2396987317703210
OAI identifier:

Suggested articles

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.